研究单位：[1]Beijing Konruns Pharmaceutical Co.,Ltd.[2]Cancer Institute and Hospital,Chinese Academy of Medical Sciences[3]National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College[4]West China Hospital[5]Beijing Tongren Hospital
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.
